51
Participants
Start Date
March 2, 2022
Primary Completion Date
February 15, 2023
Study Completion Date
July 25, 2023
UBX1325 injection 50 μL
Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28
EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28.
Rand Eye Institute, Deerfield Beach
Retina Vitreous Associates of Florida, St. Petersburg
Midwest Eye, Carmel
Mayo Clinic-Rochester, Rochester
University Retina and Macula Associates, Lemont
Illinois Eye Center, Peoria
Valley Retina Institute, McAllen
Austin Retina Associates, Round Rock
Retina Research Institution of Texas, Abilene
Advanced Vision Research Institute, Longmont
Sierra Eye Associates, Reno
Retina-Vitreous Associates Medical Group, Beverly Hills
Salehi Retina Institute, Huntington Beach
EyeHealth Northwest, Portland
Unity Biotechnology, Inc.
INDUSTRY